Medindia LOGIN REGISTER
Medindia

Side effect(s) of Eculizumab


Review the side-effects of Eculizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  Infections:
Meningococcal infections with symptoms of headache, fever, nausea, vomiting, stiff neck or stiff back, rash, muscle aches, flu-like syndrome and /or increased sensitivity of eyes to light; upper respiratory tract infections and urinary tract infections.

  Gastrointestinal:
Nausea, vomiting, stomach pain, diarrhea, constipation

  Allergy:
Allergy to the drug may include a severe anaphylactic reaction.

  Central nervous system:
Headache, difficulty in falling asleep

  Muscular:
Muscle, back, limb and/or joint pain.

  Respiratory:
Sore throat, cough, sinusitis, runny nose.

  Cardiovascular:
High blood pressure, fluid accumulation, increase in heart rate, low blood pressure.

  Kidney:
Reduced kidney function

  Blood:
Anemia, low white blood cell count, low blood potassium levels. Excessive clotting of blood may occur after stopping treatment in patients with atypical hemolytic uremic syndrome

  Skin:
Rash, itching.

Other Precautions :

Avoid excess dosage. Discontinue the drug if the patient suffers from severe meningococcal infections.

Drug Name : Eculizumab

Eculizumab(Soliris) generic Eculizumab is a monoclonal antibody, which is prescribed for two conditions: • Paroxysmal nocturnal hemoglobinuria (PNH) in which red blood cells (RBCs) are broken down resulting in anemia and decreased oxygen supply to the body. • Atypical hemolytic uremic syndrome (aHUS), where small blood clots are formed which block blood supply and cause damage to kidney and other organs. Eculizumab is an orphan drug since it is used only for the above rare conditions. It acts by blocking a part of the immune system called the complement system. In paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, the complement system acts abnormally and destroys the red blood cells and increases the risk of blood clots respectively.


Trade Names for Eculizumab

International :


Soliris
Advertisement